Healthy Longevity ScienceExplore the questions behind healthy longevity. Understand the evidence, its possibilities and its limits.
9 articles
Frontiers of longevityPartial reprogramming has reached human testing. ER-100’s sponsor announced first dosing in June 2026, in an eye-disease study planning 18 adults. The trial asks first about safety; whether it improves useful vision remains unanswered. Mouse experiments provide a scientific rationale, but the human evidence dated September 21, 2026 contains no reported outcomes showing restored sight or broader rejuvenation.
Frontiers of longevityTRIIM, supported by Intervene Immune, reported improved thymus imaging in seven of nine men after a year of treatment, alongside selected immune and DNA-age changes. The study had no untreated control group. Healthy Longevity Clinic examines the promise of thymus regeneration for immune health and why the next decisive evidence should concern useful immune function, fewer serious infections and safety.
Frontiers of longevityER-100 reprogramming, telomerase mRNA, SIRT6, TRIIM thymus regeneration, senolytics, mitochondrial transplantation, cholesterol degradation, Klotho mRNA and plasma fractions target different aspects of age-related decline. This September 2026 overview compares all nine approaches, their human or preclinical evidence, and the next useful outcomes: preserved vision, stronger immunity, tissue recovery and fewer serious illnesses. Healthy Longevity Clinic explains which developments merit attention.
Frontiers of longevityTelomerase mRNA lengthened telomeres by up to about 900 DNA building blocks in cultured human cells in a 2015 experiment. Rejuvenation Technologies is developing this approach for impaired tissue maintenance, including fibrosis. Healthy Longevity Clinic examines the potential for tissue repair, the gap between cell results and patient outcomes, and why delivery and long-term safety are central to clinical progress.
Frontiers of longevityGenflow reports that its SIRT6 gene therapy met the main DNA-based age endpoint in 24 older beagles. The announcement provides no numerical effect size, so the extent and practical meaning of the result remain unclear. Healthy Longevity Clinic examines the findings alongside earlier mouse research and asks what complete safety, physical-function and survival data would add.
Frontiers of longevitySENISCA is developing RNA-splicing approaches to change how senescent cells behave, with programs in lung fibrosis and skin health. Laboratory studies show that selected cell functions can recover, although DNA damage and other responses do not always improve together. Healthy Longevity Clinic compares this strategy with senolytics and asks whether it could preserve tissue function without unsafe cell growth.
Frontiers of longevitySemaglutide and tirzepatide can reduce lean tissue as well as fat. Exercise and adequate nutrition help make strength and independence central to weight-loss care. Bimagrumab has human body-composition results; MitoRx’s MTRX31 and Juvena’s JUV-161 explore further muscle-preserving approaches at earlier stages. Healthy Longevity Clinic compares what the findings mean for physical function, beyond a lower number on the scale.
Frontiers of longevityArtery plaque can shrink. Established cholesterol-lowering treatment reduces cardiovascular events and has produced modest plaque shrinkage in human imaging trials. Repair Biotechnologies is investigating a different approach: helping liver cells process excess cholesterol. Its mouse findings support further research, but do not establish how much human plaque would shrink, whether heart attacks would fall, or whether the treatment is safe in people.
Frontiers of longevityMitochondrial transplantation has produced encouraging early heart-recovery findings. In one small comparison, 8 of 10 treated children came off heart-lung support for at least a week, versus 4 of 14 controls. Mitrix Bio is developing separate infusion and bioreactor programs. Healthy Longevity Clinic examines the prospects for recovery, physical capacity and independence, and the evidence each approach still needs.